EGFR and non-small cell lung carcinoma: Non-small cell lung cancer with EGFR mutations are particularly sensitive to EGFR TKIs erlotinib and gefitinib, however resistance often occurs within 10–14 months of treatment, frequently due to the acquisition of the EGFR T790M “gatekeeper” mutation (Oxnard et al., 2011; Landi and Cappuzzo, 2015).